Stationed within the meninges, squads of immune cells lie in wait, ready to unleash an inflammatory assault within the brain if needed. Holding these trigger-happy troops back during peacetime falls ...

Joseph Arboleda-Velasquez of Harvard Medical School praised the results. “Ye’s group has now provided compelling evidence showing increased binding affinity of ApoE3 Christchurch for tau and its ...

The U.S. Food and Drug Administration approved Eisai and Biogen’s application for IV maintenance dosing of lecanemab on January 27. Previously, the label called for biweekly IV dosing. The new ...

C-terminal amidation is a PTM that involves the addition of an amid group to the C-terminus of a peptide or protein. Currently there is no direct evidence to suggest that C-terminal amidation of ...

For each structural strain of tau fibrils, they identified amino acids without which the strain cannot form its signature ...

This approach uses mesenchymal stem cells isolated from a patient’s own fat tissue to treat neurodegenerative diseases. The stem cells are supposed to assist in repair of damaged tissue and ...

Do you know a conference you think we should list? Let us know by sending us an email with the details to [email protected].

Tau hyperphosphorylation and conformational changes in the brain parenchyma start around seven months. Tangle-like pathology is mainly observed in the brain stem and spinal cord, and to a lesser ...

This transgenic model of tauopathy expresses MAPT with the P301S mutation, which is associated with autosomal-dominant disease in humans. The hTau.P301S model recapitulates several molecular, cellular ...

Already have an account? Log in.